



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Gerhard Binder  
gerhard.binder@med.uni-tuebingen.de

<sup>†</sup>These authors have contributed  
equally to this work and share  
first authorship

SPECIALTY SECTION  
This article was submitted to  
Pediatric Endocrinology,  
a section of the journal  
Frontiers in Endocrinology

RECEIVED 16 August 2022  
ACCEPTED 12 September 2022  
PUBLISHED 27 September 2022

CITATION  
Apel A, Iliev DI, Urban C, Weber K,  
Schweizer R, Blumenstock G,  
Pasche S, Nieratschker V and Binder G  
(2022) Corrigendum: GH  
responsiveness is not correlated to  
*IGF1* P2 promoter methylation in  
children with Turner syndrome, GHD  
and SGA short stature.  
*Front. Endocrinol.* 13:1020804.  
doi: 10.3389/fendo.2022.1020804

COPYRIGHT  
© 2022 Apel, Iliev, Urban, Weber,  
Schweizer, Blumenstock, Pasche,  
Nieratschker and Binder. This is an  
open-access article distributed under  
the terms of the [Creative Commons  
Attribution License \(CC BY\)](#). The use,  
distribution or reproduction in other  
forums is permitted, provided the  
original author(s) and the copyright  
owner(s) are credited and that the  
original publication in this journal is  
cited, in accordance with accepted  
academic practice. No use,  
distribution or reproduction is  
permitted which does not comply with  
these terms.

# Corrigendum: GH responsiveness is not correlated to *IGF1* P2 promoter methylation in children with Turner syndrome, GHD and SGA short stature

Anja Apel<sup>1†</sup>, Daniel I. Iliev<sup>1†</sup>, Christina Urban<sup>1</sup>, Karin Weber<sup>1</sup>,  
Roland Schweizer<sup>1</sup>, Gunnar Blumenstock<sup>2</sup>, Sarah Pasche<sup>3</sup>,  
Vanessa Nieratschker<sup>3</sup> and Gerhard Binder<sup>1\*</sup>

<sup>1</sup>Pediatric Endocrinology, University Children's Hospital Tübingen, Tübingen, Germany,  
<sup>2</sup>Department of Clinical Epidemiology and Applied Biometry, University of Tübingen,  
Tübingen, Germany, <sup>3</sup>Department of Psychiatry and Psychotherapy, Tübingen Center for Mental  
Health, University Hospital Tübingen, Tübingen, Germany

## KEYWORDS

IGF-1, promotor methylation, GH response, prediction, short stature, GH treatment

## A Corrigendum on:

**GH responsiveness is not correlated to *IGF1* P2 promoter methylation  
in children with Turner syndrome, GHD and SGA short stature**

by Apel A, Iliev DI, Urban C, Weber K, Schweizer R, Blumenstock G, Pasche S, Nieratschker V  
and Binder G (2022) *Front. Endocrinol.* 13:897897. doi: 10.3389/fendo.2022.897897

In the published article, there was an error in **Table 1**. The values of height SDS at and after start of treatment were wrong. The corrected **Table 1** and its caption "Clinical characteristics and GHR polymorphism status of the patients (mean ± SD)" appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Clinical characteristics and GHR polymorphism status of the patients (mean  $\pm$  SD).

Diagnosis	GHD	SGA short stature	Turner syndrome
n	40	36	16
Female/male; n	11/29	12/24	16/0
Birth length; cm	48.9 $\pm$ 4.2	41.5 $\pm$ 7.2	48.1 $\pm$ 2.8
Birth length; SDS	-0.12 $\pm$ 1.18	-2.15 $\pm$ 1.46	-0.12 $\pm$ 1.17
Birth weight; g	2,917 $\pm$ 729	1,893 $\pm$ 794	2,867 $\pm$ 633
Birth weight; SDS	-0.67 $\pm$ 1.16	-2.52 $\pm$ 1.06	-0.65 $\pm$ 1.08
Target height; cm	172.0 $\pm$ 7.7	169.4 $\pm$ 7.2	164.0 $\pm$ 5.4
Age at start of treatment; y (median (range))	5.2 (0.3–11.9)	6.0 (0.6–9.8)	5.3 (3.9–11.6)
Bone age at start of treatment; y	4.7 $\pm$ 2.2	4.9 $\pm$ 2.1	6.5 $\pm$ 3.1
Height at start of treatment; SDS	-3.9 $\pm$ 1.2	-3.9 $\pm$ 0.9	-3.4 $\pm$ 0.7
RhGH dose; $\mu$ g/kg*d	28.4 $\pm$ 6.7	39.1 $\pm$ 5.6	46.2 $\pm$ 3.1
Height 1 y after start of treatment; SDS	-2.7 $\pm$ 0.8	-3.0 $\pm$ 1.1	-2.8 $\pm$ 0.8
Height velocity at start of treatment; cm/y	5.0 $\pm$ 1.1	5.5 $\pm$ 1.1	5.6 $\pm$ 2.2
Height velocity 1 y after start of treatment; cm/y	9.9 $\pm$ 1.9	8.9 $\pm$ 1.0	9.1 $\pm$ 1.5
Delta height velocity; cm/y	4.7 $\pm$ 1.5	3.4 $\pm$ 1.4	3.6 $\pm$ 3.3
IGF-1 at start of treatment; SDS	-4.2 $\pm$ 1.9	-1.7 $\pm$ 1.5	-1.5 $\pm$ 1.1
IGF-1 1 y after start of treatment; SDS	-1.0 $\pm$ 1.2	0.7 $\pm$ 1.3	1.2 $\pm$ 0.7
Delta IGF-1 SDS under treatment; SDS	3.2 $\pm$ 1.7	2.4 $\pm$ 1.5	2.5 $\pm$ 1.2
IGFBP-3 at start of treatment; SDS	-3.2 $\pm$ 1.8	-1.6 $\pm$ 1.3	-1.8 $\pm$ 1.2
IGFBP-3 1 y after start of treatment; SDS	-1.0 $\pm$ 1.2	-0.1 $\pm$ 1.0	-0.8 $\pm$ 0.7
Delta IGFBP-3 SDS under treatment; SDS	2.3 $\pm$ 1.9	1.5 $\pm$ 1.2	1.0 $\pm$ 0.9
Studentized residuals of 1st y prediction	0.53 $\pm$ 1.1	1.48 $\pm$ 1.2	0.32 $\pm$ 1.4
GHR polymorphism; wt-wt/wt-del3/del3-del3; n	24/16/0	16/16/4	6/9/1

For calculation of height velocity, patients aged <4 y at start of rhGH treatment were excluded (n = 13).